JP2019517589A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517589A5
JP2019517589A5 JP2019516103A JP2019516103A JP2019517589A5 JP 2019517589 A5 JP2019517589 A5 JP 2019517589A5 JP 2019516103 A JP2019516103 A JP 2019516103A JP 2019516103 A JP2019516103 A JP 2019516103A JP 2019517589 A5 JP2019517589 A5 JP 2019517589A5
Authority
JP
Japan
Prior art keywords
cells
car
dose
subject
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019516103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517589A (ja
JP7139318B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/036231 external-priority patent/WO2017214207A2/en
Publication of JP2019517589A publication Critical patent/JP2019517589A/ja
Publication of JP2019517589A5 publication Critical patent/JP2019517589A5/ja
Priority to JP2021199037A priority Critical patent/JP2022033929A/ja
Application granted granted Critical
Publication of JP7139318B2 publication Critical patent/JP7139318B2/ja
Priority to JP2023189795A priority patent/JP2023184646A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019516103A 2016-06-06 2017-06-06 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 Active JP7139318B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021199037A JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2023189795A JP2023184646A (ja) 2016-06-06 2023-11-07 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662346547P 2016-06-06 2016-06-06
US62/346,547 2016-06-06
US201662417292P 2016-11-03 2016-11-03
US62/417,292 2016-11-03
US201662429737P 2016-12-03 2016-12-03
US62/429,737 2016-12-03
PCT/US2017/036231 WO2017214207A2 (en) 2016-06-06 2017-06-06 Methods for the treatment of b cell malignancies using adoptive cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021199037A Division JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Publications (3)

Publication Number Publication Date
JP2019517589A JP2019517589A (ja) 2019-06-24
JP2019517589A5 true JP2019517589A5 (enExample) 2020-07-16
JP7139318B2 JP7139318B2 (ja) 2022-09-20

Family

ID=59227902

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019516103A Active JP7139318B2 (ja) 2016-06-06 2017-06-06 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2021199037A Pending JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2023189795A Pending JP2023184646A (ja) 2016-06-06 2023-11-07 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021199037A Pending JP2022033929A (ja) 2016-06-06 2021-12-08 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法
JP2023189795A Pending JP2023184646A (ja) 2016-06-06 2023-11-07 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法

Country Status (11)

Country Link
US (2) US20200016199A1 (enExample)
EP (1) EP3463437A2 (enExample)
JP (3) JP7139318B2 (enExample)
KR (3) KR20240036704A (enExample)
CN (1) CN109562151A (enExample)
AU (1) AU2017277396B2 (enExample)
BR (1) BR112018074406A2 (enExample)
CA (1) CA3024725A1 (enExample)
MA (1) MA45341A (enExample)
MX (2) MX2018014911A (enExample)
WO (1) WO2017214207A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209690B1 (en) 2014-10-20 2021-05-05 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
CA3012827A1 (en) 2016-02-02 2017-08-10 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
US20190298772A1 (en) * 2016-11-03 2019-10-03 Juno Therapeutics, Inc. Combination therapy of a t cell-based therapy and a btk inhibitor
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
ES2988795T3 (es) 2017-02-27 2024-11-21 Juno Therapeutics Inc Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
JP7359751B2 (ja) 2017-03-14 2023-10-11 ジュノー セラピューティクス インコーポレイテッド 極低温保管のための方法
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
EP3678690A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
KR20250010043A (ko) 2017-10-18 2025-01-20 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US20210145882A1 (en) * 2018-04-13 2021-05-20 Fred Hutchinson Cancer Research Center Methods for adoptive cell therapy targeting ror1
EP3787751A1 (en) * 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
WO2020092475A1 (en) * 2018-10-31 2020-05-07 The Children's Hospital Of Philadelphia T cells from lymphatic fluid for diagnostic and therapeutic use
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
FI3886875T3 (fi) * 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
ES2986007T3 (es) * 2018-11-30 2024-11-08 Juno Therapeutics Inc Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
BR112021026382A2 (pt) * 2019-06-27 2022-02-08 Crispr Therapeutics Ag Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
CN115398231A (zh) * 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
US20230071910A1 (en) * 2020-01-24 2023-03-09 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
IL295384A (en) * 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
EP4153616A4 (en) * 2020-05-18 2024-08-21 Robert Sackstein COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20230263890A1 (en) * 2020-06-05 2023-08-24 Tessa Therapeutics Ltd. Treatment of cd30-positive cancer
WO2021260657A1 (en) * 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
AU2021366431A1 (en) * 2020-10-20 2023-05-18 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
RU2758126C1 (ru) * 2021-04-02 2021-10-26 федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации Способ прогнозирования развития рецидива диффузной В-крупноклеточной лимфомы
WO2022226355A2 (en) * 2021-04-23 2022-10-27 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
WO2022254337A1 (en) * 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
EP4712987A2 (en) * 2023-06-27 2026-03-25 Nkarta, Inc. Methods for treatment using cd19-directed immunotherapies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
AU2001265346A1 (en) 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
DK2433713T3 (en) 2007-12-07 2017-09-25 Miltenyi Biotec Gmbh CELL PROCESSING SYSTEMS AND PROCEDURES
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN102209729B (zh) * 2008-11-07 2016-05-25 安进研发（慕尼黑）股份有限公司 小儿急性淋巴细胞白血病的治疗方法
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US9751928B2 (en) 2012-05-03 2017-09-05 Fred Hutchinson Cancer Research Center Enhanced affinity T cell receptors and methods for making the same
HRP20250822T1 (hr) * 2012-07-13 2025-09-26 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a
KR102264290B1 (ko) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
CN112458057A (zh) 2012-10-02 2021-03-09 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus

Similar Documents

Publication Publication Date Title
JP2019517589A5 (enExample)
Wang et al. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
JP7682820B2 (ja) Ｃａｒの抗腫瘍活性のための毒性管理
Pianko et al. Immune checkpoint blockade for hematologic malignancies: a review
Hude et al. The emerging role of immune checkpoint inhibition in malignant lymphoma
Fong et al. Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment
JP2024059707A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
JP2024023318A (ja) 二重特異性抗体の組成物及びその使用方法
Honeychurch et al. Immuno-regulatory antibodies for the treatment of cancer
Cabo et al. Trial watch: immunostimulatory monoclonal antibodies for oncological indications
JP2017530694A5 (enExample)
EP3548083A1 (en) Methods for modulation of car-t cells
Katsin et al. CAR-T cell therapy for classical Hodgkin lymphoma
US20190287013A1 (en) Methods for determining dosing of a therapeutic agent and related treatments
JP7704748B2 (ja) 逐次抗ｃｄ１９治療
Lam et al. Pharmacokinetics and pharmacodynamics of immunotherapy
Iriyama Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma
HK40116181A (en) Toxicity management for anti-tumor activity of cars
HK40116181B (en) Toxicity management for anti-tumor activity of cars
WO2025096517A1 (en) Factors for optimizing immunotherapy efficacy
HK40069741B (en) Toxicity management for anti-tumor activity of cars
HK40069741A (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars